Table 15.
Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC | NAL | CIP | AZM | COL | SMX | TMP | TET |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Austria | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47.2 | 47.2 | 0 | 0 | 41.7 | 0 | 41.7 |
Belgium | 175 | 1.1 | 1.7 | 22.9 | 3.4 | 1.7 | 0 | 2.3 | 54.3 | 56 | 8 | 1.7 | 57.1 | 27.4 | 17.1 |
Croatia | 56 | 0 | 0 | 1.8 | 0 | 0 | 0 | 0 | 98.2 | 98.2 | 0 | 0 | 33.9 | 0 | 32.1 |
Cyprus | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 12.5 | 81.3 | 81.3 | 0 | 0 | 75 | 75 | 81.3 |
Czech Republic | 34 | 0 | 0 | 26.5 | 0 | 0 | 0 | 0 | 47.1 | 47.1 | 0 | 2.9 | 38.2 | 0 | 38.2 |
Denmarka | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Germany | 18 | 0 | 11.1 | 44.4 | 0 | 0 | 0 | 5.6 | 61.1 | 61.1 | 0 | 16.7 | 50 | 50 | 44.4 |
Greecea | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 100 | 0 | 0 | 0 | 0 | 0 |
Hungary | 76 | 1.3 | 0 | 5.3 | 0 | 1.3 | 0 | 7.9 | 82.9 | 82.9 | 0 | 0 | 76.3 | 0 | 76.3 |
Irelanda | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Malta | 10 | 40 | 20 | 60 | 0 | 0 | 0 | 0 | 70 | 70 | 0 | 0 | 90 | 10 | 80 |
Netherlands | 25 | 4 | 0 | 16 | 4 | 4 | 0 | 4 | 80 | 80 | 0 | 0 | 84 | 68 | 68 |
Poland | 33 | 3 | 0 | 27.3 | 0 | 0 | 0 | 0 | 51.5 | 69.7 | 0 | 0 | 45.5 | 0 | 42.4 |
Portugal | 33 | 0 | 39.4 | 66.7 | 39.4 | 39.4 | 0 | 0 | 0 | 36.4 | 3 | 0 | 63.6 | 39.4 | 66.7 |
Romania | 82 | 8.5 | 3.7 | 24.4 | 0 | 0 | 0 | 0 | 59.8 | 61 | 0 | 0 | 67.1 | 9.8 | 67.1 |
Slovakia | 83 | 0 | 0 | 26.5 | 0 | 0 | 0 | 1.2 | 66.3 | 69.9 | 0 | 1.2 | 53 | 1.2 | 51.8 |
Slovenia | 17 | 0 | 0 | 17.6 | 0 | 0 | 0 | 0 | 100 | 94.1 | 0 | 0 | 100 | 0 | 100 |
Spain | 48 | 4.2 | 0 | 4.2 | 0 | 0 | 0 | 16.7 | 68.8 | 68.8 | 0 | 6.3 | 29.2 | 4.2 | 41.7 |
United Kingdom | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.8 | 11.8 | 5.9 |
Total (19 MSs) | 763 | 2.4 | 3 | 19.7 | 2.6 | 2.4 | 0 | 3 | 61.5 | 64.7 | 2 | 1.4 | 55.6 | 14.8 | 46.1 |
Icelanda | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ECOFFs: epidemiological cut‐off values; EUCAST: European Committee on Antimicrobial Susceptibility Testing; N: number of isolates tested; MSs: Member States; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.
The occurrence of resistance is assessed on less than 10 isolates and should only be considered as part of the total of MSs data.